Complement in monoclonal antibody therapy of cancer

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are established targeted cancer therapies with variable clinical outcomes.
• The mechanisms underlying mAb efficacy, particularly the role of immune system engagement, require further elucidation.
• Complement activation and immune effector cell interactions are critical components of mAb-mediated anti-tumor responses.

Purpose of the Study:

• To review the role of complement system activation in the efficacy of monoclonal antibody cancer therapy.
• To explore how complement-dependent and antibody-dependent mechanisms influence anti-tumor activity.
• To provide insights for improving current mAb therapies and designing novel antibody-based treatments for cancer.

Main Methods:

• Literature review of approved monoclonal antibodies for cancer treatment.
• Analysis of the dual role of complement (agonistic and antagonistic) in modulating mAb anti-tumor effects.
• Examination of complement's impact on direct tumor cell signaling, immune cell engagement, and the tumor microenvironment.

Main Results:

• Monoclonal antibodies engage the immune system via complement activation and antibody receptors on immune cells, contributing to tumor cell killing.
• Complement can enhance anti-tumor activity through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
• Complement's influence on the tumor microenvironment and its dual role in modulating mAb efficacy present a complex interplay.

Conclusions:

• The intricate balance of complement's agonistic and antagonistic effects significantly impacts the clinical efficacy of monoclonal antibody therapy.
• Understanding these complement-mediated mechanisms is crucial for optimizing existing mAb treatments.
• Harnessing knowledge of complement pathways can guide the development of next-generation therapeutic antibodies for improved cancer treatment outcomes.